Albemarle Withdraws Bid to Acquire Liontown Resources

US specialty chemicals company Albemarle has announced that it will not pursue a binding agreement to purchase Liontown Resources and has formally withdrawn its non-binding offer.

On Sep. 3, Liontown had received a revised conditional and non-binding indicative proposal from Albemarle to acquire all of the outstanding shares in Liontown for A$3.00 in cash per share via scheme of arrangement. The revised proposal valued Liontown at A$6.6 billion ($4.3 billion) on an equity value basis.

"Our engagement with the Liontown team has been meaningful and productive. We appreciate the level of cooperation we have received, and we thank the entire team for their efforts," said Kent Masters, CEO of Albemarle. "That said, moving forward with the acquisition, at this time, is not in Albemarle's best interests."

The stated that growing complexities associated with the proposed transaction were a factor in its decision.

Albemarle said it will continue to pursue its long-term growth strategy and that its capital allocation priorities remain high-yield organic and inorganic growth, maintaining the company's financial flexibility and investment-grade credit rating, and funding its dividends.

Albemarle Withdraws Bid to Acquire Liontown Resources

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read